FF/UMEC/VI population | Non-ELLIPTA MITT population | FF/UMEC/VI versus non-ELLIPTA MITT | |
Patients | 910 | 904 | |
FEV1# | |||
Patients | 691 | 675 | |
FEV1 mL | 1446 (1425–1467) | 1396 (1375–1418) | 50 (26–73); p<0.001 |
FEV1 mL change from baseline | 77 (57–98) | 28 (6–49) | |
Trough FEV1 | |||
Patients | 301 | 292 | |
FEV1 mL | 1498 (1462–1534) | 1445 (1404–1486) | 53 (9–96); p=0.017 |
FEV1 mL change from baseline¶ | 100 (64–135) | 47 (6–88) |
Data are presented as n or least-squares mean (95% CI), unless otherwise stated. FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; MITT: multiple-inhaler triple therapy. #: data include both trough and non-trough values; ¶: patients with imputed FEV1, n=82 (FF/UMEC/VI), n=115 (non-ELLIPTA MITT). Trough FEV1 is defined as the FEV1 value recorded while patients have withheld COPD maintenance, short-acting β2-agonist and short-acting muscarinic receptor antagonist treatment. For COPD maintenance treatments taken once daily, FEV1 was considered as trough if the patient withheld the LABA and LAMA components of the maintenance treatment for ≥16 h. For COPD maintenance treatments taken twice daily, FEV1 was considered as trough if the patient withheld the LABA and LAMA components of the maintenance treatment for ≥8 h.